

Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond

September 17, 2020 - With the explosive excitement and clinical proof of concepts utilizing CD47 approaches, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47.



The digital [2nd Macrophage-directed Therapies Summit](#) (October 27-29) is focused on optimizing the potential of macrophage therapies, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond.

Bringing together the leading experts, we will explore the clinical development of CD47 checkpoint blockades, combination strategies, macrophage repolarization approaches and engineered macrophages.

[View the full event guide](#) to see all the leading speakers and their agenda sessions.

Some highlights on the 2020 agenda:

- **Nicholas Poirier**, Chief Scientific Officer, **OSE Immunotherapeutics** will explore a novel 'don't eat me' target regulating macrophages phagocytosis and dendritic cell antigen presentation
- **Michael Klichinsky**, Co-Founder & VP, Discovery, **Carisma Therapeutics** will discuss genetically engineering CAR macrophages & CAR monocytes
- **Yang Liu**, Founder, President and Chief Scientific Officer, **Oncoimmune** will explore the CD24–Siglec-10 pathway as a novel innate immune checkpoint to modulate anti-tumor immunity
- **Gloria Lin**, Associate Director of Translational Research, **Trillium Therapeutics** Inc will reveal emerging clinical data on SIRPaFc decoy receptors that neutralize the suppressive effects of CD47

To see the full speaker line up, [download the full agenda](#)

Hear from our previous attendee:

"The Macrophage-directed Therapies Summit was an outstanding assembly of leaders from academia and industry that advanced our understanding of macrophages in health and disease." **Dana-Farber Cancer Institute**

Join the trailblazers of macrophage therapeutic development as we come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.

hansonwade

52 Grosvenor Gardens | London | SW1W 0AU
T: +44 (0)203 8541 748
W: www.hansonwade.com

